1. OP0011 A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS. (2nd June 2020) Authors: Merkel, P. A.; Jayne, D.; Yue, H.; Schall, T.; Kelleher, C.; Bekker, P. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0046 Effect of a selective c5ar antagonist, avacopan (CCX168), on plasma complement levels in anca associated vasculitis (AAV). (12th June 2018) Authors: Bunch, D.O.; Deng, J.; McInnis, E.A.; Bekker, P.; Hillson, J.L.; Schall, T.J.; Jennette, C.J.; Nachman, P.; Deng, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0203 Orally-administered CCR1 antagonist CCX354-C in a phase 2 rheumatoid arthritis study. (23rd January 2014) Authors: Tak, P.P.; Balanescu, A.; Tseluyko, V.; Bojin, S.; Drescher, E.; Dairaghi, D.; Miao, S.; Marchesin, V.; Jaen, J.; Schall, T.J.; Bekker, P. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0227 Oral C5a Receptor Antagonist CCX168 Phase 2 Clinical TRIAL in Anca-Associated Renal Vasculitis. (10th June 2014) Authors: Jayne, D.R.; Bruchfeld, A.; Schaier, M.; Ciechanowski, K.; Harper, L.; Jadoul, M.; Segelmark, M.; Selga, D.; Szombati, I.; Venning, M.; Hugo, C.; Van Daele, P.L.; Viklicky, O.; Potarca, A.; Schall, T.J.; Bekker, P. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗